MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vertex Pharmaceuticals Inc

Closed

SectorHealthcare

483.28 -0.22

Overview

Share price change

24h

Current

Min

479.62

Max

487.51

Key metrics

By Trading Economics

Income

-132M

913M

Sales

142M

2.9B

P/E

Sector Avg

30.42

63.778

EPS

3.98

Profit margin

31.353

Employees

6,100

EBITDA

-99M

1.2B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+2.96% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2025

Market Stats

By TradingEconomics

Market Cap

6.8B

127B

Previous open

483.5

Previous close

483.28

News Sentiment

By Acuity

12%

88%

14 / 386 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Vertex Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 lut 2025, 22:11 UTC

Earnings

Vertex Pharmaceuticals Posts Higher 4Q Revenue

31 sty 2025, 00:19 UTC

Major Market Movers

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

19 gru 2024, 12:25 UTC

Major Market Movers

Vertex Pharmaceuticals Shares Drop on Mixed Results in Drug Trial

4 lis 2024, 21:44 UTC

Earnings

Vertex Pharmaceuticals Raises Full-Year Outlook After 3Q Earnings

1 sie 2024, 20:45 UTC

Earnings

Vertex Pharmaceuticals Upgrades Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

11 lut 2025, 21:12 UTC

Earnings

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

11 lut 2025, 14:21 UTC

Earnings

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. -- IBD

10 lut 2025, 21:12 UTC

Earnings

Vertex Pharmaceuticals: Duncan McKechnie, Current Head of N Amer Comml, to Assume Role of Chief Comml Officer

10 lut 2025, 21:12 UTC

Earnings

Vertex Pharmaceuticals CFO Charlie Wagner to Assume Additional Role of COO

10 lut 2025, 21:11 UTC

Earnings

Vertex Pharmaceuticals COO Stuart Arbuckle Plans to Retire July 1

10 lut 2025, 21:04 UTC

Earnings

Vertex Pharmaceuticals Sees Combined Non-GAAP R&D, AIPR&D and SG&A Expenses $4.9B to $5.0 B >VRTX

10 lut 2025, 21:04 UTC

Earnings

Vertex Pharmaceuticals Sees Combined GAAP R&D, AIPR&D and SG&A Expenses $5.55B to $5.7 B >VRTX

10 lut 2025, 21:02 UTC

Earnings

Vertex Pharmaceuticals Sees 2025 Rev $11.75B-$12B >VRTX

10 lut 2025, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Rev $2.91B >VRTX

10 lut 2025, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Net $913M >VRTX

10 lut 2025, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q Adj EPS $3.98 >VRTX

10 lut 2025, 21:01 UTC

Earnings

Vertex Pharmaceuticals 4Q EPS $3.50 >VRTX

31 sty 2025, 09:59 UTC

Hot Stocks

Stocks to Watch Friday: Intel, Apple, Vertex, Samsung -- WSJ

4 lis 2024, 22:21 UTC

Earnings

Vertex Beats Expectations, But Needs More To Drive 'Another Leg Of Stock Upside' -- IBD

4 lis 2024, 21:25 UTC

Earnings

Vertex Pharmaceuticals Beats Third-Quarter Estimates As Pain Treatment Looms -- IBD

4 lis 2024, 21:03 UTC

Earnings

Vertex Pharmaceuticals: Raising Full-Yr Pdt Rev Guidance to $10.8B to $10.9B >VRTX

4 lis 2024, 21:01 UTC

Earnings

Vertex Pharmaceuticals 3Q Adj EPS $4.38 >VRTX

4 lis 2024, 21:01 UTC

Earnings

Vertex Pharmaceuticals 3Q Net $1.05B >VRTX

4 lis 2024, 21:01 UTC

Earnings

Vertex Pharmaceuticals 3Q EPS $4.01 >VRTX

26 wrz 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

1 sie 2024, 20:30 UTC

Earnings

Vertex Pharmaceuticals Ups Revenue Outlook on Cystic Fibrosis, Sickle-Cell Treatments

1 sie 2024, 20:03 UTC

Earnings

Vertex Pharmaceuticals: Raised Full Yr Pdt Rev Guidanceto $10.65B - $10.85 B >VRTX

1 sie 2024, 20:02 UTC

Earnings

Vertex Pharmaceuticals: Increasing Our Full Yr Pdt Rev Guidance >VRTX

1 sie 2024, 20:02 UTC

Earnings

Vertex Pharmaceuticals 2Q Rev $2.65B >VRTX

Peer Comparison

Price change

Vertex Pharmaceuticals Inc Forecast

Price Target

By TipRanks

2.96% upside

12 Months Forecast

Average 499.09 USD  2.96%

High 591 USD

Low 320 USD

Based on 27 Wall Street analysts offering 12 month price targets forVertex Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

27 ratings

16

Buy

10

Hold

1

Sell

Technical Score

By Trading Central

480.95 / 505Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

14 / 386 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.